Jw Life Science Corp (234080) - Total Assets
Based on the latest financial reports, Jw Life Science Corp (234080) holds total assets worth ₩310.01 Billion KRW (≈ $210.09 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Jw Life Science Corp (234080) shareholders funds for net asset value and shareholders' equity analysis.
Jw Life Science Corp - Total Assets Trend (2015–2024)
This chart illustrates how Jw Life Science Corp's total assets have evolved over time, based on quarterly financial data.
Jw Life Science Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Jw Life Science Corp's total assets of ₩310.01 Billion consist of 32.5% current assets and 67.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.3% |
| Accounts Receivable | ₩42.66 Billion | 13.1% |
| Inventory | ₩35.45 Billion | 10.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩3.47 Billion | 1.1% |
| Goodwill | ₩74.27 Billion | 22.8% |
Asset Composition Trend (2015–2024)
This chart illustrates how Jw Life Science Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jw Life Science Corp market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jw Life Science Corp's current assets represent 32.5% of total assets in 2024, an increase from 21.6% in 2015.
- Cash Position: Cash and equivalents constituted 2.3% of total assets in 2024, up from 0.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 22.8% of total assets.
Jw Life Science Corp Competitors by Total Assets
Key competitors of Jw Life Science Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Jw Life Science Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.21 | 2.09 | 0.82 |
| Quick Ratio | 0.81 | 1.70 | 0.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩17.15 Billion | ₩64.55 Billion | ₩-12.77 Billion |
Jw Life Science Corp - Advanced Valuation Insights
This section examines the relationship between Jw Life Science Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.95 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 27.2% |
| Total Assets | ₩325.32 Billion |
| Market Capitalization | $135.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jw Life Science Corp's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jw Life Science Corp's assets grew by 27.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jw Life Science Corp (2015–2024)
The table below shows the annual total assets of Jw Life Science Corp from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩325.32 Billion ≈ $220.47 Million |
+27.16% |
| 2023-12-31 | ₩255.84 Billion ≈ $173.38 Million |
+1.14% |
| 2022-12-31 | ₩252.94 Billion ≈ $171.42 Million |
+15.25% |
| 2021-12-31 | ₩219.47 Billion ≈ $148.73 Million |
+0.65% |
| 2020-12-31 | ₩218.04 Billion ≈ $147.76 Million |
+8.26% |
| 2019-12-31 | ₩201.40 Billion ≈ $136.49 Million |
+0.27% |
| 2018-12-31 | ₩200.86 Billion ≈ $136.12 Million |
+1.17% |
| 2017-12-31 | ₩198.53 Billion ≈ $134.54 Million |
+3.27% |
| 2016-12-31 | ₩192.24 Billion ≈ $130.28 Million |
+6.87% |
| 2015-12-31 | ₩179.88 Billion ≈ $121.90 Million |
-- |
About Jw Life Science Corp
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed … Read more